<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221117056529N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-10</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>reduce pain after laparoscopic gynecological procedures</public_title>
      <acronym></acronym>
      <scientific_title>The effect of intraperitoneal spillage of rupivacaine and ketamine in combination with  lung recruitment to reduce pain after laparoscopic gynecological procedures</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67076</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using random numbers table, they will be randomly divided into two groups of 25 people
in the study and 25 people in the control group. In such a way that in the event of odd, they
would be in rupivacaine and ketamine and in the event of even, they would be in Sodium Chloride 0.9%
group, Blinding description: The administration of anesthesia and fluids (volume and type of serum) during anesthesia
is performed by an anesthesiologist and anesthesia technician, and all data will be collected
and recorded in the checklist by an anesthesiologist who is unaware of the division of the
groups. patient are also unaware of the division of the
groups.</study_design>
      <phase>3</phase>
      <hc_freetext>The effects of the combination of ropivacaine and ketamine, pain reduction, laparoscopic surgeries for women.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 50 women who have undergone laparoscopic surgery will be injected with ropivacaine 0.2% and ketamine 0.5 mg/kg in a total volume of 50 cc by the surgeon into the intraperitoneal space and the surgical site. In the control group, 50 cc of 0.09% normal saline serum will be used. Before the removal of trocars in both groups, lung recruitment maneuver will be performed. In the PACU, the patient will be monitored and treated if there is a specific complication. The severity of shoulder and abdominal pain, the degree of sedation will be recorded every 15 minutes until delivery to the ward, and in case of VAS scores higher than 3, treatment will be given, and the dose of supplementary drugs will also be recorded. Intervention 2: Control group: After surgery, 50 cc of normal saline will be used in the control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A part of the data, such as information related to the main outcome or the like, can be shared.

When:
Access starts from 1401

To whom:
It will be available for researchers working in academic and scientific institutions and even people working in industry.

Conditions:
Data must be protected

Where to obtain:
Samin Ehsaninezhad 09364702225fu

How to obtain:
Immediately after calling

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reyhane Abri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>AL zahra hospital,Bagh shomal square,Artesh street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۵۱۳۸۶۶۵۷۹۳</zip>
        <telephone>+98 41 3553 9160</telephone>
        <email>reyhane.abri@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reyhane Abri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>AL zahra hospital,Bagh shomal square,Artesh street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۵۱۳۸۶۶۵۷۹۳</zip>
        <telephone>+98 41 3553 9160</telephone>
        <email>reyhane.abri@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>II or I ASA class , candidates for laparoscopic surgery for women in the age range of 18-60 years in Al-Zahra Hospital, Tabriz
Patient consent to enter the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>The existence of any contraindications to the use of ropivacaine and other local anesthetics
The presence of any contraindications for ketamine use: history of seizures, psychological disorders, hypertension, high intracerebral pressure, etc.
Hypersensitivity to ropivacaine or other local anesthetics and ketamine
Concomitant systemic diseases such as any history of cardiovascular, pulmonary, liver, kidney, etc.
Presence of chronic pain in the patient
Addiction to the use of painkillers and drugs
Patient dissatisfaction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T88.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complication of surgical and medical care, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 50 women who have undergone laparoscopic surgery will be injected with ropivacaine 0.2% and ketamine 0.5 mg/kg in a total volume of 50 cc by the surgeon into the intraperitoneal space and the surgical site. In the control group, 50 cc of 0.09% normal saline serum will be used. Before the removal of trocars in both groups, lung recruitment maneuver will be performed. In the PACU, the patient will be monitored and treated if there is a specific complication. The severity of shoulder and abdominal pain, the degree of sedation will be recorded every 15 minutes until delivery to the ward, and in case of VAS scores higher than 3, treatment will be given, and the dose of supplementary drugs will also be recorded.</i_keyword>
      <i_keyword>Control group: After surgery, 50 cc of normal saline will be used in the control group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The percentage of people in whom abdominal and shoulder pain has decreased after laparoscopic surgeries. Timepoint: Upon entering the operating room, standard monitoring including NIBP, HR, RR, ECG, SPO2, and ETCo2 is done and will continue. The severity of shoulder and abdominal pain is recorded every 15 minutes until the patient's complete recovery and delivery to the ward. Method of measurement: The severity of shoulder and abdominal pain, based on VAS score and degree of sedation according to Ramsay sedation score, is recorded every 15 minutes until the patient's complete recovery and delivery to the ward.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-12</approval_date>
        <contact_name>Ethics committee of Tabriz Medical Sciences</contact_name>
        <contact_address>Talash dormitory ,Pish ghadam,kamar bandiye miyani Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
